Hemophilia care: Current guidelines and applications of new factor concentrates

Size: px
Start display at page:

Download "Hemophilia care: Current guidelines and applications of new factor concentrates"

Transcription

1 Hemophilia care: Current guidelines and applications of new factor concentrates K Fischer MD PhD Van Creveldkliniek University Medical Center, Utrecht, The Netherlands

2 Guidelines identified: WFH UKHCDO 2010 Richards. BJH 2010; 149: 498 France 2009 Meurnier S. Arch de Pediatrie 2009; 16:1571 USA 2007 MASAC, nr 179; Dutch 2009 NVHB, ISBN Germany 2008 not published in journal

3 Things to consider when making treatment decisions

4 Half life increases with age for FVIII only FVIII ±8 15 hours FIX ± 20 hours Björkman S. Blood 2012;119: Björkman S. Haemophilia 2001; 16:

5 Trough levels appear most important in children Age 1-6 yrs If FVIII>1% 2 7 days/wk: Children: 40% 90% no bleeds Age yrs Adults: 20% 54% no bleeds Collins P. JTH 2008; 7: 413

6 Long(er) acting concentrates technique Factor VIII Pegylation (n=3) Fc fusion (n=1) VWD binding (n=1) Factor IX Half life X 1.5 X 3-5 Registered Prophylactic regimens used in studies Alprolix (USA, CA, Japan) Fc fusion Pegylation (n=1) Fc fusion (n=1) Albumin fusion (n=1) Eloctate (USA, CA, Japan) Fc fusion 2-1 x/week 1x/ 2-3 weeks

7 Collins et al Haemophilia 2011; 17: 2-10 Prophylaxis with longer acting concentrates Time with low levels Peak levels

8 Collins et al Haemophilia 2011; 17: 2-10 Prophylaxis with longer acting concentrates (II) Protection during sports?

9 Natural experiment of long-term low trough levels of FVIII/IX: moderate haemophilia (I) prophylaxis Den Uijl. Haemophilia 2011; 17: 849

10 Natural experiment of long-term low trough levels of FVIII/IX: moderate haemophilia (II) N=75, age 34 yrs Den Uijl. Blood Transfusion 2014; 12 Suppl 1: S330

11 Very young children do not bleed very often annual no of joint bleeds age cum no of joint bleeds Fischer et al, Acta Radiol 2002;43:528 Collins P. JTH 2008; 7: 413

12 Powell J et al BJH 2014;epub Sept 11 Experience with long acting FIX 25/28 patients used FIX prophylaxis 2-4 times weekly On study: 50 IU/kg 2x/wk, or 100 IU/kg 1x/wk, or 50 IU/kg1x/wk Sports not mentioned

13 Considerations for prophylactic treatment Bleeding is dependent on FVIII levels, especially in children FVIII half life increases with age from ±8 to ±15 hours More frequent infusions allow for maintanance of trough levels with lower dosages FVIII levels of 1-5% protect against bleeding in most patients Some patients on long-acting FIX can get by with infusions every 2-3 weeks

14 Recommendations and new concentrates: starting prophylaxis Timing: by 2nd joint bleed/significant soft tissue bleed. (UK) Or max 2 bleeds/1 joint or 3 bleeds in diff joints (FR) unaffected by new concentrates Initial dose/frequency: May start 1x/wk dose IU/kg increase rapidly (UK) 50 IU/kg 1x /wk (FR) if started with 1x/wk, unaffected if started 3x/wk consider starting 2x/wk?

15 Recommendations and new concentrates: prophylactic regimen Current FVIII concentrates UK: IU/kg 3-3.5x/wk trough not always >1% lowest dose to prevent bleeds daily dosing more efficient MASAC: IU/kg 3-3.5x levels 1% FR: 3x 30 or 3.5 x IU/kg NL: x IU/kg or according to bleeding Longer-acting FVIII concentrates Studies: Clinical practice: 2x IU/kg 65 IU/kg every 5 days 75 IU/kg once weekly Should we follow the example from the study protocols?

16 Dosing current and long-acting concentrates: children Double dose small effect & frequent dosing still needed

17 Dosing current and long-acting concentrates: children Regimen used In study protocols Twice weekly dosing is very inefficient

18 Dosing current and long-acting concentrates: adults Less infusions are more feasible in adults

19 Recommendations and new concentrates: prophylactic regimen Initiating prophylaxis Continuing prophylaxis By 2nd joint bleed/significant soft tissue bleed May start 1x/wk dose IU/kg increase rapidly Full dose protocol consider starting 2x/wk in stead of 3x/wk?? If half life < 10 hours: Keep at 3-3.5x/wk, perhaps dose If half life 10 hours: Interval hours, dose = Or interval = and dose Consider PK dosing Timing of infusions according ot sports activities!

20 Thank you -Danke Schön

Hemophilia: diagnostics and treatment

Hemophilia: diagnostics and treatment Hemophilia: diagnostics and treatment Eveline Mauser-Bunschoten Van Creveldkliniek department of benign hematology thrombosis and hemostasis What is hemophilia? Hemophilia A: deficiency of factor VIII

More information

Improving Patient Outcomes in the Management of Hemophilia. Disclosures

Improving Patient Outcomes in the Management of Hemophilia. Disclosures Improving Patient Outcomes in the Management of Hemophilia Mark T. Reding, MD Associate Professor of Medicine Division of Hematology, Oncology, and Transplantation Director, Center for Bleeding and Clotting

More information

The Arrival of Longer Lasting Recombinant Products for Hemophilia. Steven Pipe, MD University of Michigan Ann Arbor, MI

The Arrival of Longer Lasting Recombinant Products for Hemophilia. Steven Pipe, MD University of Michigan Ann Arbor, MI Test The Arrival of Longer Lasting Recombinant Products for Hemophilia Steven Pipe, MD University of Michigan Ann Arbor, MI Disclosures for: Steven Pipe Conflict Research Support Director, Officer, Employee

More information

PLEASE REFER TO UKHCDO WEBSITE TO ENSURE YOU ARE USING THE MOST RECENT VERSION OF THIS PROTOCOL

PLEASE REFER TO UKHCDO WEBSITE TO ENSURE YOU ARE USING THE MOST RECENT VERSION OF THIS PROTOCOL PLEASE REFER TO UKHCDO WEBSITE TO ENSURE YOU ARE USING THE MOST RECENT VERSION OF THIS PROTOCOL http://www.ukhcdo.org UKHCDO protocol for first line immune tolerance induction for children with severe

More information

Afstyla. (antihemophilic factor [recombinant] single chain) New Product Slideshow

Afstyla. (antihemophilic factor [recombinant] single chain) New Product Slideshow Afstyla (antihemophilic factor [recombinant] single chain) New Product Slideshow Introduction Brand name: Afstyla Generic name: Antihemophilic Factor (recombinant), single chain Pharmacological class:

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Clotting Factors and Antithrombin Effective Date... 4/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 8007 Table of Contents Coverage Policy...

More information

Keywords: bleeding, haemarthrosis, haemophilia, joint bleeding, pharmacokinetic-guided treatment, prophylaxis, rahf- PFM

Keywords: bleeding, haemarthrosis, haemophilia, joint bleeding, pharmacokinetic-guided treatment, prophylaxis, rahf- PFM Haemophilia (16), 22, 514 5 DOI:.1111/hae.1295 ORIGINAL ARTICLE Clinical haemophilia Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every

More information

The First rfviii WITH A PROLONGED HALF-LIFE

The First rfviii WITH A PROLONGED HALF-LIFE Visit ELOCTATEpro.com for more information The First rfviii WITH A PROLONGED HALF-LIFE Indications ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is a recombinant DNA derived, antihemophilic

More information

WHEN TO START ITI? 4/15/2013. Starting and stopping ITI. Jan Blatný

WHEN TO START ITI? 4/15/2013. Starting and stopping ITI. Jan Blatný Starting and stopping ITI? Jan Blatný Department of Paediaric Haematology Children s University Hospital Masaryk University Brno, Czech Republic Starting and stopping ITI Starting and/or stopping ITI is

More information

Choicing therapeutic goals and accomplishing regimens

Choicing therapeutic goals and accomplishing regimens Choicing therapeutic goals and accomplishing regimens the purchaser the treating physician the resources the patient (and caregivers) the social tissue Identifying challenges and barriers Previous clinical

More information

Idelvion. (coagulation factor IX [recombinant], albumin fusion protein) New Product Slideshow

Idelvion. (coagulation factor IX [recombinant], albumin fusion protein) New Product Slideshow Idelvion (coagulation factor IX [recombinant], albumin fusion protein) New Product Slideshow Introduction Brand name: Idelvion Generic name: Coagulation factor IX (recombinant), albumin fusion protein

More information

Acquired Inhibitors of Coagulation

Acquired Inhibitors of Coagulation Acquired Inhibitors of Coagulation Christine L Kempton, MD, MSc Emory University Disclosures for In compliance with COI policy, ISTH requires the following disclosures to the session audience: Research

More information

Hemophilia A (factor VIII deficiency) and Hemophilia B (factor IX deficiency) are the most

Hemophilia A (factor VIII deficiency) and Hemophilia B (factor IX deficiency) are the most Pharmacotherapeutics Recent Advance of Pharmacotherapy in Hemophilia Young Shil Park, MD Department of Pediatrics, Kyunghee University College of Medicine E - mail : pysmd@khnmc.or,kr J Korean Med Assoc

More information

UK Standards of Care

UK Standards of Care UK Standards of Care Service Provision of Physiotherapy For Adults with Haemophilia & other Inherited Bleeding Disorders Page 1 of 10 Background Standards were originally written by the Haemophilia Chartered

More information

Coding Implications Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information.

Coding Implications Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.PHAR.215 Effective Date: 05.01.16 Last Review Date: 02.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this policy

More information

Coagulation Factor IX FC Fusion Protein (Alprolix): Treatment Cost Comparison and Budget Impact Analysis

Coagulation Factor IX FC Fusion Protein (Alprolix): Treatment Cost Comparison and Budget Impact Analysis CADTH TECHNOLOGY REVIEW Coagulation Factor IX FC Fusion Protein (Alprolix): Treatment Cost Comparison and Budget Impact Analysis Product Line: Technology Review Version: 1.0 Issue Number: 1 Publication

More information

Prophylaxis & Arthropathy

Prophylaxis & Arthropathy Prophylaxis & Arthropathy On-Demand and Prophylaxis Treatment Coagulation factor replacement may be given when a bleed occurs (on-demand therapy) or before bleeding occurs, to prevent bleeds (prophylactic

More information

UK Standards of Care

UK Standards of Care UK Standards of Care Service Provision of Physiotherapy For Children with Haemophilia & other Inherited Bleeding Disorders Page 1 of 10 Background Standards were originally written by the Haemophilia Chartered

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.PHAR.215 Effective Date: 05.01.16 Last Review Date: 02.19 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important Reminder at

More information

Inhibitors in Patients With Hemophilia Elena Santagostino MD, PhD

Inhibitors in Patients With Hemophilia Elena Santagostino MD, PhD Inhibitors in Patients With Hemophilia Elena Santagostino MD, PhD Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Fondazione Ca Granda - Ospedale Maggiore Policlinico and University of Milan Milan,

More information

Inhibitors in children and in adults Why they are different and what do they have common?

Inhibitors in children and in adults Why they are different and what do they have common? Inhibitors in children and in adults Why they are different and what do they have common? Jan Blatny, MD, PhD Petr Smejkal, MD, PhD Depts. of Paediatric/ Clinical Haematology Centre for Thrombosis and

More information

Von Willebrand Disease: Management and Complications. Mike Makris Sheffield, UK

Von Willebrand Disease: Management and Complications. Mike Makris Sheffield, UK Von Willebrand Disease: Management and Complications Mike Makris Sheffield, UK Disclosures for Mike Makris Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific

More information

Albutrepenonacog alfa (Idelvion ) for the treatment of Italian patients with hemophilia B: a budget impact model

Albutrepenonacog alfa (Idelvion ) for the treatment of Italian patients with hemophilia B: a budget impact model Farmeconomia. Health economics and therapeutic pathways 2018; 19(1): 1-10 https://doi.org/10.7175/fe.v19i1.1328 Albutrepenonacog alfa (Idelvion ) for the treatment of Italian patients with hemophilia B:

More information

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ELOCTATE. Antihemophilic Factor (Recombinant BDD), Fc Fusion Protein

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ELOCTATE. Antihemophilic Factor (Recombinant BDD), Fc Fusion Protein PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ELOCTATE Antihemophilic Factor (Recombinant BDD), Fc Fusion Protein Lyophilized Powder for Solution 250, 500, 750, 1000, 1500, 2000 and 3000 IU/vial

More information

4/15/2013. The Marathon. 24 years ago in former Czechoslovakia. Jan Blatný

4/15/2013. The Marathon. 24 years ago in former Czechoslovakia. Jan Blatný The Czech way to Haemophilia Care Jan Blatný Department of Paediatric Haematology University Hospital Brno & Masaryk University Brno, CZ The Marathon As in any race It is NOT enough to start the run! Do

More information

Haematology Subcommittee of PTAC Meeting held 16 March 2016

Haematology Subcommittee of PTAC Meeting held 16 March 2016 Haematology Subcommittee of PTAC Meeting held 16 March 2016 (minutes for web publishing) The Haematology Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology

More information

Treatment of Patients with Haemophilia in China: Sub-analysis of the HERO study

Treatment of Patients with Haemophilia in China: Sub-analysis of the HERO study Treatment of Patients with Haemophilia in China: Sub-analysis of the HERO study Baolai HUA Peking Union Medical College Hospital On behalf of Chinese HERO National Advisory Board 12-OCT-2013 Slide 1 Japanese

More information

Anita Shah 1 Alexander Solms. Verzhiniya Avramova 4 Stanislav Simeonov

Anita Shah 1 Alexander Solms. Verzhiniya Avramova 4 Stanislav Simeonov Clin Pharmacokinet (207) 56:045 055 DOI 0.007/s40262-06-0492-2 ORIGINAL RESEARCH ARTICLE Improved Pharmacokinetics with Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized

More information

Thirtyyearsofhemophilia treatment in. the Netherlands, Chapter 2.2

Thirtyyearsofhemophilia treatment in. the Netherlands, Chapter 2.2 Chapter 2.2 Thirtyyearsofhemophilia treatment in the Netherlands,1972-2001 Iris Plug, Johanna G. van der Bom, Marjolein Peters, Eveline P. Mauser-Bunschoten, Arja de Goede-Bolder, LilyHeijnen, Cees Smit,

More information

Factane : from product characteristics to clinical efficiency The experience in immune tolerance induction

Factane : from product characteristics to clinical efficiency The experience in immune tolerance induction Factane : from product characteristics to clinical efficiency The experience in immune tolerance induction Prof. Benoît POLACK, MD, PhD University Hospital - Grenoble, France CNRS UJF UMR 5525 Adana, May

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Human - Alphanate, Humate-P, Wilate) Reference Number: ERX.SPA.185 Effective Date: 01.11.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.PHAR.215 Effective Date: 05.01.16 Last Review Date: 02.19 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important Reminder at

More information

Approach to bleeding disorders &treatment. by RAJESH.N General medicine post graduate

Approach to bleeding disorders &treatment. by RAJESH.N General medicine post graduate Approach to bleeding disorders &treatment by RAJESH.N General medicine post graduate 2 Approach to a patient of bleeding diathesis 1. Clinical evaluation: History, Clinical features 2. Laboratory approach:

More information

João A. Abrantes 1, Alexander Solms 2, Dirk Garmann 3, Elisabet I. Nielsen 1, Siv Jönsson 1, Mats O. Karlsson 1

João A. Abrantes 1, Alexander Solms 2, Dirk Garmann 3, Elisabet I. Nielsen 1, Siv Jönsson 1, Mats O. Karlsson 1 Integrated modelling of factor VIII activity kinetics, occurrence of bleeds and individual characteristics in haemophilia A patients using a full random effects modelling (FREM) approach João A. Abrantes

More information

Clinical picture of Von Willebrand disease in the Netherlands

Clinical picture of Von Willebrand disease in the Netherlands Clinical picture of Von Willebrand disease in the Netherlands 20 th Annual Meeting BSTH, Antwerp 22 november 2012 Prof. Dr Frank W.G. Leebeek ErasmusMC Rotterdam The Netherlands Von Willebrand Disease

More information

Peri-operative strategy in patients with congenital disorders of haemostasis

Peri-operative strategy in patients with congenital disorders of haemostasis 06RC1 - Filipescu Peri-operative strategy in patients with congenital disorders of haemostasis Daniela Filipescu Cardiac Anaesthesia and Intensive Care Medicine, Iliescu Emergency Cardiovascular Diseases

More information

RECENT MAJOR CHANGES Warnings and Precautions (5.1) 12/2017

RECENT MAJOR CHANGES Warnings and Precautions (5.1) 12/2017 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ELOCTATE safely and effectively. See full prescribing information for ELOCTATE. ELOCTATE [Antihemophilic

More information

Clinical practice of prophylaxis in severe haemophilia: navigating between the burden of treatment and risk of arthropathy.

Clinical practice of prophylaxis in severe haemophilia: navigating between the burden of treatment and risk of arthropathy. Clinical practice of prophylaxis in severe haemophilia: navigating between the burden of treatment and risk of arthropathy Annelies Nijdam ISBN 978-94-6169-806-3 Copyright A. Nijdam, 2015 No part of this

More information

Dr Simon McRae Department of Haematology SA Pathology

Dr Simon McRae Department of Haematology SA Pathology Dr Simon McRae Department of Haematology SA Pathology Normally defined as factor VIII levels >5-40 IU/dL Proportion of patients with mild HA varies between centres - 32% patients with mild HA in a large

More information

van Galen KPM, Engelen ET, Mauser-Bunschoten EP, van Es RJJ, Schutgens REG

van Galen KPM, Engelen ET, Mauser-Bunschoten EP, van Es RJJ, Schutgens REG Cochrane Database of Systematic Reviews Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions(review)

More information

University of Groningen

University of Groningen University of Groningen Long-term impact of joint bleeds in von Willebrand disease van Galen, Karin P. M.; de Kleijn, Piet; Foppen, Wouter; Eikenboom, Jeroen; Meijer, Karina; Schutgens, Roger E. G.; Fischer,

More information

Hemlibra (emicizumab-kxwh) NEW PRODUCT SLIDESHOW

Hemlibra (emicizumab-kxwh) NEW PRODUCT SLIDESHOW Hemlibra (emicizumab-kxwh) NEW PRODUCT SLIDESHOW Introduction Brand name: Hemlibra Generic name: Emicizumab-kxwh Pharmacological class: Bispecific factor IXa- and factor X-directed antibody Strength and

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Shima M, Hanabusa H, Taki M, et al. Factor VIII mimetic function

More information

Rapid Report A13-07 Version 1.0 Treatment of Hemophilia Patients May 28, 2015

Rapid Report A13-07 Version 1.0 Treatment of Hemophilia Patients May 28, 2015 Executive Summary On October 11, 2012, the German Federal Ministry of Health (BMG) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to assess the treatment of hemophilia patients.

More information

Hemofílie. MUDr.Ivan Vonke, MBA OKH, Nemocnice České Budějovice, a.s.

Hemofílie. MUDr.Ivan Vonke, MBA OKH, Nemocnice České Budějovice, a.s. Hemofílie e MUDr.Ivan Vonke, MBA OKH, Nemocnice České Budějovice, a.s. Hemophilia Incidence: Hemopilia A (deficiency of factor VIII): 1-2 of 10 000 male newborns in all ethnic groups Hemophilia B (deficiency

More information

Impact of Adopting Population Pharmacokinetics for Tailoring Prophylaxis in Haemophilia A Patients: A Historically Controlled Observational Study

Impact of Adopting Population Pharmacokinetics for Tailoring Prophylaxis in Haemophilia A Patients: A Historically Controlled Observational Study 368 Coagulation and Fibrinolysis THIEME Impact of Adopting Population Pharmacokinetics for Tailoring Prophylaxis in Haemophilia A Patients: A Historically Controlled Observational Study Michaela Stemberger

More information

The role of plasma products in the treatment of haemophila today. Scott Dunkley Haemophilia and Thrombosis Unit Royal Prince Alfred Hospital Sydney

The role of plasma products in the treatment of haemophila today. Scott Dunkley Haemophilia and Thrombosis Unit Royal Prince Alfred Hospital Sydney The role of plasma products in the treatment of haemophila today Scott Dunkley Haemophilia and Thrombosis Unit Royal Prince Alfred Hospital Sydney Inhibitors remain the greatest challenge to haemophilia

More information

Contents 1 Bleeding disorders Haemophilia... 12

Contents 1 Bleeding disorders Haemophilia... 12 Contents 1 Bleeding disorders... 5 1.1 Features of a bleeding disorder... 5 1.2 First line diagnostic investigations... 5 1.2.1 Clotting screens... 6 1.3 Further investigations... 6 1.3.1 Investigation

More information

Study design: Multicenter, randomized, controlled, cross-over, blinded PK comparison

Study design: Multicenter, randomized, controlled, cross-over, blinded PK comparison Brand Name 1, 2 : Rixubis Generic Name 1, 2 : Coagulation factor IX recombinant Manufacturer 5 : Baxter Drug Class 1, 2, 3 : Antihemophilic agent Labeled Uses 1, 2 : Hemophilia B hemorrhage, routine prophylaxis,

More information

Predicting severity of haemophilia A and B splicing mutations by information analysis

Predicting severity of haemophilia A and B splicing mutations by information analysis Haemophilia (2006), 12, 258 262 DOI: 10.1111/j.1365-2516.2006.01216.x Predicting severity of haemophilia A and B splicing mutations by information analysis Y. VON KODOLITSCH*, J. BERGER and P. K. ROGANà

More information

Efficacy of standard prophylaxis versus ondemand

Efficacy of standard prophylaxis versus ondemand Pediatric Hematology and Oncology ISSN: 0888-0018 (Print) 1521-0669 (Online) Journal homepage: http://www.tandfonline.com/loi/ipho20 Efficacy of standard prophylaxis versus ondemand treatment with bayer's

More information

Lonoctocog Alfa: A Review in Haemophilia A

Lonoctocog Alfa: A Review in Haemophilia A Drugs (2017) 77:1677 1686 DOI 10.1007/s40265-017-0815-0 ADIS DRUG EVALUATION Lonoctocog Alfa: A Review in Haemophilia A Zaina T. Al-Salama 1 Lesley J. Scott 1 Published online: 12 September 2017 Ó Springer

More information

National Haemophilia Database Dataset

National Haemophilia Database Dataset Haemophilia Centre Name Diagnosis Title Surname Forename Previous Surname Previous Forename Sex NHS / CHI / HSC number Date of Birth Date of Death (if applicable) Post-mortem performed (if applicable)

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Willebrand Factor Complex (Human - Alphanate, Humate-P, Wilate) Reference Number: ERX.SPA.185 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the

More information

The legally binding text is the original French version

The legally binding text is the original French version The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 28 March 2007 FACTANE 100 I.U. /ml, powder and solvent for solution for injection Box of 1 2.5 ml vial (CIP: 562 115-5)

More information

TRANSPARENCY COMMITTEE OPINION. 10 March 2010

TRANSPARENCY COMMITTEE OPINION. 10 March 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 March 2010 FIBROGAMMIN 62.5 U/ml, powder and solvent for injection or infusion B/1 Powder in vial + 4 ml of solvent

More information

This slide describes the process of records validation within the registry.

This slide describes the process of records validation within the registry. 1 This slide describes the process of records validation within the registry. 2 3 Centres contributing to the CNHP registry. 4 Though the percentage of PWH over 65 years has not been increasing dramatically

More information

Utilization evaluation of factor concentration and frequency of bleeds among patients with haemophilia A and haemophilia B in northwest Iran

Utilization evaluation of factor concentration and frequency of bleeds among patients with haemophilia A and haemophilia B in northwest Iran Utilization evaluation of factor concentration and frequency of bleeds among patients with haemophilia A and haemophilia B in northwest Iran Abstract Roya Dolatkhah 1, Morteza Ghojazadeh 2, Iraj Asvadi-Kermani

More information

Arthropathy after joint bleeding in patients with Von Willebrand disease

Arthropathy after joint bleeding in patients with Von Willebrand disease REVIEW HEMATOLOGY 253 Arthropathy after joint bleeding in patients with Von Willebrand disease K.P.M. van Galen, MD, MSc, E.P. Mauser-Bunschoten, MD, PhD SUMMARY Von Willebrand disease is the most common

More information

Mini Pool Plasma Fractionation: A Pragmatic Approach to Fill in Gaps of Supply and Access

Mini Pool Plasma Fractionation: A Pragmatic Approach to Fill in Gaps of Supply and Access Mini Pool Plasma Fractionation: A Pragmatic Approach to Fill in Gaps of Supply and Access Magdy El Ekiaby, MD Egypt 7th Annual Bioplasma World Asia 2018 12 to 13 September 2018 Singapore Global FVIII

More information

96 Current Management of Hemophilia

96 Current Management of Hemophilia C H A P T E R 96 Current Management of Hemophilia S Usha INTRODUCTION Haemophilia is an X-linked congenital bleeding disorder caused by a deficiency of clotting factor VIII (Haemophilia A) or factor IX

More information

Clinical Commissioning Policy: Immune Tolerance Induction (ITI) for haemophilia A (all ages)

Clinical Commissioning Policy: Immune Tolerance Induction (ITI) for haemophilia A (all ages) Clinical Commissioning Policy: Immune Tolerance Induction (ITI) for haemophilia A (all ages) Reference: NHS England: 16042/P NHS England INFORMATION READER BOX Directorate Medical Operations and Information

More information

Method of Viral Inactivation or Depletion. Generation/ Human or Animal Protein in Culture. Third/ None 1. Immunoaffinity

Method of Viral Inactivation or Depletion. Generation/ Human or Animal Protein in Culture. Third/ None 1. Immunoaffinity TABLE I. Products Licensed in the U.S. to Treat HEMOPHILIA A A. Recombinant FACTOR VIII Concentrates The table includes bioengineered recombinant factor concentrates with altered properties such as extended

More information

Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate. From: European Plasma Fractionation Association (EPFA)

Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate. From: European Plasma Fractionation Association (EPFA) Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate Application for retention on the WHO Model List From: European Plasma Fractionation Association (EPFA) 1. Summary

More information

Coagulation Factor IX (Recombinant), Albumin Fusion Protein

Coagulation Factor IX (Recombinant), Albumin Fusion Protein IDELVION Product Monograph Instructions for Use The IDELVION Product Monograph is presented as an interactive PDF. To locate information quickly and easily, click the appropriate section within the Table

More information

Is monitoring of azole concentrations of clinical value in patients with haematological malignancies?

Is monitoring of azole concentrations of clinical value in patients with haematological malignancies? Is monitoring of azole concentrations of clinical value in patients with haematological malignancies? J Peter Donnelly PhD Department of Haematology Radboud University Nijmegen Medical Centre Nijmegen,

More information

PRODUCT MONOGRAPH ALPROLIX. Coagulation Factor IX (Recombinant), Fc Fusion Protein

PRODUCT MONOGRAPH ALPROLIX. Coagulation Factor IX (Recombinant), Fc Fusion Protein PRODUCT MONOGRAPH ALPROLIX Coagulation Factor IX (Recombinant), Fc Fusion Protein Lyophilized Powder for Solution 250, 500, 1000, 2000, 3000 and 4000 IU/vial Antihemorrhagic Blood Coagulation Factor IX

More information

HEMLIBRA (emicizumab-kxwh) IN HEMOPHILIA A WITH INHIBITORS

HEMLIBRA (emicizumab-kxwh) IN HEMOPHILIA A WITH INHIBITORS HEMLIBRA (emicizumab-kxwh) IN HEMOPHILIA A WITH INHIBITORS Media Inquiries: (650) 467-6800 About HEMLIBRA HEMLIBRA (emicizumab-kxwh) is approved by the FDA as a prophylactic medicine used to prevent or

More information

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment. PHA 5127 Final Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers

More information

The status of care for persons with von Willebrand disease registered within CNHP registry Annual Report 2017

The status of care for persons with von Willebrand disease registered within CNHP registry Annual Report 2017 The status of care for persons with von Willebrand disease registered within CNHP registry Annual Report 2017 Jan Blatný, Petra Ovesná on behalf of Centres contributing to database of the CNHP (Czech National

More information

Peer Review Report #1. Desmopressin. (1) Does the application adequately address the issue of the public health need for the medicine?

Peer Review Report #1. Desmopressin. (1) Does the application adequately address the issue of the public health need for the medicine? 20 th Expert Committee on Selection and Use of Essential Medicines Peer Review Report #1 Desmopressin (1) Does the application adequately address the issue of the public health need for the medicine? Desmopressin

More information

Session 1 : Fibrinogen deficiencies

Session 1 : Fibrinogen deficiencies 13 th Workshop on Thrombosis and Paediatric Haemostasis Marseille, 13 th October 2010 Session 1 : Fibrinogen deficiencies Clinical, biological and therapeutic concerns : P De Moerloose, Geneva Genetic

More information

End-Stage Hemophilic Arthropathy: The Journey to Joint Replacement

End-Stage Hemophilic Arthropathy: The Journey to Joint Replacement Slide no 1 End-Stage Hemophilic Arthropathy: The Journey to Joint Replacement Husam Darwish, MD, FRCSC Asst. Professor and Consultant Department of Orthopaedic Surgery King Abdulaziz University Jeddah,

More information

Treatment of von Willebrand disease. Jenny Goudemand Haematology Department University Hospital of Lille - France

Treatment of von Willebrand disease. Jenny Goudemand Haematology Department University Hospital of Lille - France Treatment of von Willebrand disease Jenny Goudemand Haematology Department University Hospital of Lille - France French registries on VWD Inclusion criteria FranceCoag Network French Institute for Public

More information

Medication Prior Authorization Form

Medication Prior Authorization Form Section I Member Information Name (Last, First, Middle Initial) Date of Birth WEA Trust Subscriber Number Diagnosis Page 2 1. MEDICATION 2. STRENGTH 3. DIRECTIONS 4. QUANTITY FEIBA NF NovoSeven RT HEMOFIL

More information

The association of haemophilic arthropathy with Health-Related Quality of Life: a post hoc analysis

The association of haemophilic arthropathy with Health-Related Quality of Life: a post hoc analysis Haemophilia (2016), 22, 833 840 DOI: 10.1111/hae.13120 ORIGINAL ARTICLE Clinical haemophilia The association of haemophilic arthropathy with Health-Related Quality of Life: a post hoc analysis K. FISCHER,*

More information

Introduction. to that of unaffected individuals. 3 Indeed, the life expectancy. years between 1990 and

Introduction. to that of unaffected individuals. 3 Indeed, the life expectancy. years between 1990 and 1 TABLE OF CONTENTS Introduction Case 1: Jose C. Clinical Discussion Case 2: Andrew P. Clinical Discussion Case 3: Chris W. Clinical Discussion Summary References Hemophilia Clinical Consults: Inhibitor

More information

Management of haemophilia with inhibitors in resourceconstrained

Management of haemophilia with inhibitors in resourceconstrained Earn 3 CPD Points online Haemophilia Masterclass Dr Johan Potgieter Pathologist Department of Haematology NHLS - TAD University of Pretoria Management of haemophilia with inhibitors in resourceconstrained

More information

Hepatitis C infection among Dutch haemophilia patients: a nationwide cross-sectional study of prevalence and antiviral treatment

Hepatitis C infection among Dutch haemophilia patients: a nationwide cross-sectional study of prevalence and antiviral treatment Haemophilia (2005), 11, 270 275 DOI: 10.1111/j.1365-2516.2005.01083.x Hepatitis C infection among Dutch haemophilia patients: a nationwide cross-sectional study of prevalence and antiviral treatment D.POSTHOUWER*,I.PLUG,

More information

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation guideline The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation Charles R. M. Hay, S. Brown, P. W. Collins, D. M. Keeling

More information

PREOPERATIVE PREPARATION AND ANAESTHETIC MANAGEMENT OF A PATIENT WITH HAEMOPHILIA A

PREOPERATIVE PREPARATION AND ANAESTHETIC MANAGEMENT OF A PATIENT WITH HAEMOPHILIA A Int. J. Pharm. Med. & Bio. Sc. 2012 Manjunath, 2012 Case Report ISSN 2278 5221 www.ijpmbs.com Vol. 1, No. 1, July 2012 2012 IJPMBS. All Rights Reserved PREOPERATIVE PREPARATION AND ANAESTHETIC MANAGEMENT

More information

Central venous lines in haemophilia.

Central venous lines in haemophilia. Central venous lines in haemophilia. Ljung, Rolf Published in: Haemophilia DOI: 10.1046/j.1365-2516.9.s1.7.x 2003 Link to publication Citation for published version (APA): Ljung, R. (2003). Central venous

More information

NEW ZEALAND DATA SHEET

NEW ZEALAND DATA SHEET ALPROLIX (eftrenonacog alfa) (rhu) NEW ZEALAND DATA SHEET NAME OF THE MEDICINE ALPROLIX (eftrenonacog alfa) (rhu) is a long-acting, fully recombinant fusion protein consisting of human coagulation factor

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Willebrand Factor Complex (Human - Alphanate, Humate-P, Wilate) Reference Number: ERX.SPA.185 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (DDAVP Injection, Stimate) Reference Number: CP.PHAR.214 Effective Date: 05.01.16 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace, Medicaid Coding Implications Revision

More information

RECENT MAJOR CHANGES Warnings and Precautions (5.1, 5.2) 04/2017 Dosage and Administration (2.1) 11/2017

RECENT MAJOR CHANGES Warnings and Precautions (5.1, 5.2) 04/2017 Dosage and Administration (2.1) 11/2017 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all of the information needed to use ALPROLIX safely and effectively. See full prescribing information for ALPROLIX. ALPROLIX [Coagulation

More information

Paediatric care of the child with haemophilia.

Paediatric care of the child with haemophilia. Paediatric care of the child with haemophilia. Ljung, Rolf Published in: Haemophilia DOI: 10.1046/j.1365-2516.2002.00631.x Published: 2002-01-01 Link to publication Citation for published version (APA):

More information

Recombinant Treatments for Bleeding Disorders. An overview of treatments that are considered to have a low risk of viral transmission

Recombinant Treatments for Bleeding Disorders. An overview of treatments that are considered to have a low risk of viral transmission Recombinant Treatments for Bleeding Disorders An overview of treatments that are considered to have a low risk of viral transmission History of bleeding disorder treatments Recombinant products: A significant

More information

ITI OUTCOME PREDICTORS 4/15/2013. ITI Risk Stratification in Children. ITI three main regimens. Jan Blatny, MD, PhD

ITI OUTCOME PREDICTORS 4/15/2013. ITI Risk Stratification in Children. ITI three main regimens. Jan Blatny, MD, PhD ITI Risk Stratification in Children Jan Blatny, MD, PhD Dept. of Paediatric Haematology Centre for Thrombosis and Haemostasis Children's University Hospital Brno, Czech Republic ITI three main regimens

More information

Bleeding Disorders. Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph

Bleeding Disorders. Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph Bleeding Disorders Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph Normal hemostasis The normal hemostatic response involves interactions among: The blood vessel wall (endothelium)

More information

Coagulopathy Case - 3. Andy Nguyen, M.D. 2009

Coagulopathy Case - 3. Andy Nguyen, M.D. 2009 Coagulopathy Case - 3 Andy Nguyen, M.D. 2009 CLINICAL HISTORY A 21 year-old male seen in the emergency room with a swollen, tender right knee. Patient is an electrician who had fallen to the ground an

More information

Dose and response in haemophilia optimization of factor replacement therapy

Dose and response in haemophilia optimization of factor replacement therapy review Dose and response in haemophilia optimization of factor replacement therapy Alok Srivastava Department of Haematology, Christian Medical College, Vellore, India Summary The mainstay of the management

More information

European retrospective study of real-life haemophilia treatment

European retrospective study of real-life haemophilia treatment Haemophilia (17), 23, 15 114 DOI: 1.1111/hae.13111 ORIGINAL ARTICLE Clinical haemophilia European retrospective study of real-life haemophilia treatment E. BERNTORP,* G. DOLAN, C. HAY, S. LINARI, E. SANTAGOSTINO,

More information

HEMLIBRA (emicizumab-kxwh) IN HEMOPHILIA A WITH OR WITHOUT FACTOR VIII INHIBITORS

HEMLIBRA (emicizumab-kxwh) IN HEMOPHILIA A WITH OR WITHOUT FACTOR VIII INHIBITORS HEMLIBRA (emicizumab-kxwh) IN HEMOPHILIA A WITH OR WITHOUT FACTOR VIII INHIBITORS Media Inquiries: (650) 467-6800 About Hemlibra Hemlibra (emicizumab-kxwh) is approved by the FDA as a prophylactic (preventative)

More information

Important News Regarding Helixate FS, Antihemophilic Factor (Recombinant):

Important News Regarding Helixate FS, Antihemophilic Factor (Recombinant): Important News Regarding Helixate FS, Antihemophilic Factor (Recombinant): Availability and what comes next Please see Important Safety Information on pages 10 11 and accompanying full prescribing information,

More information

ORIGINAL ARTICLE Clinical haemophilia. Introduction

ORIGINAL ARTICLE Clinical haemophilia. Introduction Haemophilia (2014), 20, 58 64 DOI: 10.1111/hae.12242 ORIGINAL ARTICLE Clinical haemophilia Long-standing prophylactic therapy vs. episodic treatment in young people with severe haemophilia: a comparison

More information

Hemophilia. Staff Training Module 2016/2017

Hemophilia. Staff Training Module 2016/2017 MISSION The Hemophilia Federation of America (HFA) is a national nonprofit organization that assists and advocates for the bleeding disorders community. Hemophilia Staff Training Module 2016/2017 Developed

More information

Coagulation BEFORE Surgery

Coagulation BEFORE Surgery Coagulation BEFORE Surgery Lorenzo ALBERIO Médecin chef Hématologie générale et Hémostase Service et Laboratoire centrale d Hématologie CHUV, Lausanne Outline 1. Pre-op testing 2. Ongoing anticoagulation

More information

SBUH Aminoglycoside Dosing Protocol

SBUH Aminoglycoside Dosing Protocol Adult Aminoglycoside Dosing for Gram negative infections prior to available serum levels (Excludes patients with cystic fibrosis, OB GYN patients and surgical prophylaxis) Cr Cl 40 ml/min 5 7 mg/kg INT

More information

Mark T. Reding, MD Associate Professor of Medicine Hematology, Oncology and Transplantation Division Director, Center for Bleeding and Clotting

Mark T. Reding, MD Associate Professor of Medicine Hematology, Oncology and Transplantation Division Director, Center for Bleeding and Clotting Mark T. Reding, MD Associate Professor of Medicine Hematology, Oncology and Transplantation Division Director, Center for Bleeding and Clotting Disorders University of Minnesota Medical School Minneapolis,

More information